FindTrial
Sign In

Effect of immunotherapy on novel coronavirus (COVID-19) infection in allergic rhinitis:a retrospective cohort research

Effect of immunotherapy on novel coronavirus (COVID-19) Infection in allergic rhinitis:a retrospective cohort research

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075113
Enrollment
Unknown
Registered
2023-08-25
Start date
2023-05-16
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis, novel coronavirus (COVID-19)

Interventions

Immunotherapy Group:N/A
Allergic rhinitis group without immunotherapy:N/A

Sponsors

The First Affiliated Hospital, Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 65 Years

Inclusion criteria

Inclusion criteria: Ability to understand questionnaire content. 3 years old = age = 65 years old, no limitation of gender AR patients who was diagnosed according to the criteria described in the Chinese Guidelines for the diagnosis and treatment of Allergic Rhinitis (2022, revision).

Exclusion criteria

Exclusion criteria: Unable to read and understand Chinese Patients with AR symptoms and/or patients receiving immunotherapy after COVID-19 infection

Design outcomes

Primary

MeasureTime frame
Rate of COVID-19 infection;Rate of hospitalization;Rate of COVID-19 pneumonia;—

Secondary

MeasureTime frame
Symptom severity;Lasting time of symptom of COVID-19;—

Countries

China

Contacts

Public ContactXinjie Zhu

The First Affiliated Hospital, Nanjing Medical University

zxj.8043@163.com+86 138 1395 0568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026